Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMJRD7A)

Drug Name

GSK3326595 Drug Info

Synonyms

JLCCNYVTIWRPIZ-NRFANRHFSA-N; 1616392-22-3; 6-[(1-acetylpiperidin-4-yl)amino]-N-[(2S)-2-hydroxy-3-(1,2,3,4-tetrahydroisoquinolin-2-yl)propyl]pyrimidine-4-carboxamide; SCHEMBL15825290; MolPort-044-813-754; BDBM178166; AKOS030528008; ZINC220119494; CS-6451; AS-53150; HY-101563; GSK3326595(EPZ015938); US9675614, 208; (S)-6-((1-acetylpiperidin-4-yl)amino)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide

Indication

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Phase 2	[1]
Non-hodgkin lymphoma	2B33.5	Phase 1	[2]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]

Cross-matching ID

PubChem CID: 90241742
CAS Number: CAS 1616392-22-3
TTD Drug ID: DMJRD7A

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Protein arginine methyltransferase 5 (PRMT5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AMG 193	DMU9K8N	Aggressive cancer	2A00-2F9Z	Phase 2	[3]
PRT811	DMW3MCX	Glioma	2A00.0	Phase 1	[4]
PRT543	DMHNZ3U	Hematologic tumour	2B33.Y	Phase 1	[5]
JNJ-64619178	DMDBW2N	Myelodysplastic syndrome	2A37	Phase 1	[6]
PF-06939999	DM7BOFR	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
DS-437	DME3WBQ	Discovery agent	N.A.	Investigative	[8]
cmp5	DMBT2ZW	Discovery agent	N.A.	Investigative	[9]
EPZ015666	DM3INX7	Discovery agent	N.A.	Investigative	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 8 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Protein arginine methyltransferase 5 (PRMT5)	TTR1D7X	ANM5_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04676516) A Phase II Window of Opportunity Trial of PRMT5 Inhibitor, GSK3326595, in Early Stage Breast Cancer (OTT-19-06). U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	AMG 193 Effective in Multiple Tumor Types. Cancer Discov. 2023 Dec 12;13(12):2492.
4	Clinical pipeline report, company report or official report of Prelude Therapeutics.
5	Clinical pipeline report, company report or official report of Prelude Therapeutics.
6	A patent review of arginine methyltransferase inhibitors (2010-2018). Expert Opin Ther Pat. 2019 Feb;29(2):97-114.
7	National Cancer Institute Drug Dictionary (drug name PF-06939999).
8	Discovery of a Dual PRMT5-PRMT7 Inhibitor. ACS Med Chem Lett. 2015 Mar 2;6(4):408-12.
9	Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation. Blood. 2015 Apr 16;125(16):2530-43.
10	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1256).